Advanced stage (III-IV) Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia in children: kinetic and pharmacologic rationale for treatment and recent results (1979-1983).

S. B. Murphy, Paul Bowman, H. O. Hustu, C. W. Berard

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Since 1979, we have treated a total of 29 children with advanced-stage B-cell tumours (diffuse undifferentiated, small non-cleaved cells): 18 stage III and three stage IV, according to a clinical staging classification (Murphy, 1980), and eight with B-cell acute lymphoblastic leukaemia (B-ALL). Treatment has been based upon appreciation of rapid tumour growth kinetics and has consisted of high-dose fractionated cyclophosphamide courses, vincristine, adriamycin and infusions of cytosine arabinoside (Ara-C) with intrathecal chemotherapy. The first 12 patients (1979-1981) received, in addition, superfractionated radiotherapy (twice a day) to the involved field (22.5 Gy) and the craniospinal axis (18 Gy). Since January 1981, radiation therapy has been omitted, and subsequent patients have received the same agents as above plus high doses of methotrexate coordinated with the escalating doses of Ara-C infusions. Toxicity has consisted mainly of universal, severe but reversible haematopoietic suppression with attendant febrile episodes. Complete-remission rate for all 29 patients has been 86%, with three early failures due to progressive disease and one death from infection. Overall disease-free survival for children with stage III disease has been excellent (78%). Initial involvement of central nervous system (CNS) and/or marrow is grave: none of three patients with stage IV lymphoma and only one of eight with B-ALL is surviving off therapy without evidence of disease, suggesting a need for alternative therapies for these cases. Results are significantly better than our historical institutional experience.

Original languageEnglish
Pages (from-to)405-418
Number of pages14
JournalIARC scientific publications
Issue number60
StatePublished - 1 Dec 1985

Fingerprint

Burkitt Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cytarabine
B-Lymphocytes
Radiotherapy
Vincristine
Therapeutics
Complementary Therapies
Methotrexate
Doxorubicin
Cyclophosphamide
Disease-Free Survival
Lymphoma
Neoplasms
Fever
Central Nervous System
Bone Marrow
Drug Therapy
Growth
Infection

Cite this

@article{8694bf2e47ce4058969ba804cfba68e8,
title = "Advanced stage (III-IV) Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia in children: kinetic and pharmacologic rationale for treatment and recent results (1979-1983).",
abstract = "Since 1979, we have treated a total of 29 children with advanced-stage B-cell tumours (diffuse undifferentiated, small non-cleaved cells): 18 stage III and three stage IV, according to a clinical staging classification (Murphy, 1980), and eight with B-cell acute lymphoblastic leukaemia (B-ALL). Treatment has been based upon appreciation of rapid tumour growth kinetics and has consisted of high-dose fractionated cyclophosphamide courses, vincristine, adriamycin and infusions of cytosine arabinoside (Ara-C) with intrathecal chemotherapy. The first 12 patients (1979-1981) received, in addition, superfractionated radiotherapy (twice a day) to the involved field (22.5 Gy) and the craniospinal axis (18 Gy). Since January 1981, radiation therapy has been omitted, and subsequent patients have received the same agents as above plus high doses of methotrexate coordinated with the escalating doses of Ara-C infusions. Toxicity has consisted mainly of universal, severe but reversible haematopoietic suppression with attendant febrile episodes. Complete-remission rate for all 29 patients has been 86{\%}, with three early failures due to progressive disease and one death from infection. Overall disease-free survival for children with stage III disease has been excellent (78{\%}). Initial involvement of central nervous system (CNS) and/or marrow is grave: none of three patients with stage IV lymphoma and only one of eight with B-ALL is surviving off therapy without evidence of disease, suggesting a need for alternative therapies for these cases. Results are significantly better than our historical institutional experience.",
author = "Murphy, {S. B.} and Paul Bowman and Hustu, {H. O.} and Berard, {C. W.}",
year = "1985",
month = "12",
day = "1",
language = "English",
pages = "405--418",
journal = "IARC scientific publications",
issn = "0300-5038",
publisher = "IARC",
number = "60",

}

TY - JOUR

T1 - Advanced stage (III-IV) Burkitt's lymphoma and B-cell acute lymphoblastic leukaemia in children

T2 - kinetic and pharmacologic rationale for treatment and recent results (1979-1983).

AU - Murphy, S. B.

AU - Bowman, Paul

AU - Hustu, H. O.

AU - Berard, C. W.

PY - 1985/12/1

Y1 - 1985/12/1

N2 - Since 1979, we have treated a total of 29 children with advanced-stage B-cell tumours (diffuse undifferentiated, small non-cleaved cells): 18 stage III and three stage IV, according to a clinical staging classification (Murphy, 1980), and eight with B-cell acute lymphoblastic leukaemia (B-ALL). Treatment has been based upon appreciation of rapid tumour growth kinetics and has consisted of high-dose fractionated cyclophosphamide courses, vincristine, adriamycin and infusions of cytosine arabinoside (Ara-C) with intrathecal chemotherapy. The first 12 patients (1979-1981) received, in addition, superfractionated radiotherapy (twice a day) to the involved field (22.5 Gy) and the craniospinal axis (18 Gy). Since January 1981, radiation therapy has been omitted, and subsequent patients have received the same agents as above plus high doses of methotrexate coordinated with the escalating doses of Ara-C infusions. Toxicity has consisted mainly of universal, severe but reversible haematopoietic suppression with attendant febrile episodes. Complete-remission rate for all 29 patients has been 86%, with three early failures due to progressive disease and one death from infection. Overall disease-free survival for children with stage III disease has been excellent (78%). Initial involvement of central nervous system (CNS) and/or marrow is grave: none of three patients with stage IV lymphoma and only one of eight with B-ALL is surviving off therapy without evidence of disease, suggesting a need for alternative therapies for these cases. Results are significantly better than our historical institutional experience.

AB - Since 1979, we have treated a total of 29 children with advanced-stage B-cell tumours (diffuse undifferentiated, small non-cleaved cells): 18 stage III and three stage IV, according to a clinical staging classification (Murphy, 1980), and eight with B-cell acute lymphoblastic leukaemia (B-ALL). Treatment has been based upon appreciation of rapid tumour growth kinetics and has consisted of high-dose fractionated cyclophosphamide courses, vincristine, adriamycin and infusions of cytosine arabinoside (Ara-C) with intrathecal chemotherapy. The first 12 patients (1979-1981) received, in addition, superfractionated radiotherapy (twice a day) to the involved field (22.5 Gy) and the craniospinal axis (18 Gy). Since January 1981, radiation therapy has been omitted, and subsequent patients have received the same agents as above plus high doses of methotrexate coordinated with the escalating doses of Ara-C infusions. Toxicity has consisted mainly of universal, severe but reversible haematopoietic suppression with attendant febrile episodes. Complete-remission rate for all 29 patients has been 86%, with three early failures due to progressive disease and one death from infection. Overall disease-free survival for children with stage III disease has been excellent (78%). Initial involvement of central nervous system (CNS) and/or marrow is grave: none of three patients with stage IV lymphoma and only one of eight with B-ALL is surviving off therapy without evidence of disease, suggesting a need for alternative therapies for these cases. Results are significantly better than our historical institutional experience.

UR - http://www.scopus.com/inward/record.url?scp=0022329553&partnerID=8YFLogxK

M3 - Article

C2 - 3905592

AN - SCOPUS:0022329553

SP - 405

EP - 418

JO - IARC scientific publications

JF - IARC scientific publications

SN - 0300-5038

IS - 60

ER -